Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.
Wirden
Marc
M
Department of Virology, INSERM EMI 0214, Pitié-Salpêtrière Hospital, Paris, France. marc.wirden@psl.ap-hop-paris.fr
Delaugerre
Constance
C
Marcelin
Anne Genevieve
AG
Ktorza
Nadine
N
Ait Mohand
Hocine
H
Dominguez
Stephanie
S
Schneider
Luminita
L
Ghosn
Jade
J
Pauchard
Michele
M
Costagliola
Dominique
D
Katlama
Christine
C
Calvez
Vincent
V
D019380:Anti-HIV Agents / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D009705:Nucleosides / Q000494:pharmacology*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012367:RNA, Viral / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D009705:Nucleosides; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase